These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 38783944)

  • 1. Application of immune checkpoint inhibitors for resectable gastric/gastroesophageal cancer.
    Lin F; Chen Y; Huang B; Ruan S; Lin J; Chen Z; Huang C; Zhao B
    Front Pharmacol; 2024; 15():1391562. PubMed ID: 38783944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Perioperative treatment in resectable gastric cancer with spartalizumab in combination with fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT): a phase II study (GASPAR).
    Dos Santos M; Lequesne J; Leconte A; Corbinais S; Parzy A; Guilloit JM; Varatharajah S; Brachet PE; Dorbeau M; Vaur D; Weiswald LB; Poulain L; Le Gallic C; Castera-Tellier M; Galais MP; Clarisse B
    BMC Cancer; 2022 May; 22(1):537. PubMed ID: 35549674
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Perioperative or neoadjuvant chemotherapy for locally advanced gastric or gastroesophageal junction cancer: from independent evidence in the West, the East, and Japan to global collaboration.
    Nakayama I; Ohashi M; Nunobe S
    Chin Clin Oncol; 2024 Feb; 13(1):8. PubMed ID: 38453658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Locally advanced gastroesophageal junction cancer with pathological complete response to neoadjuvant therapy: a case report and literature review.
    Li X; Huang Q; Lei Y; Zheng X; Dai S; Leng W; Liu M
    Ann Transl Med; 2021 Mar; 9(6):513. PubMed ID: 33850910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of neoadjuvant sintilimab, oxaliplatin and capecitabine in patients with locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: early results of a phase 2 study.
    Jiang H; Yu X; Li N; Kong M; Ma Z; Zhou D; Wang W; Wang H; Wang H; He K; Li Z; Lu Y; Zhang J; Zhao K; Zhang Y; Xu N; Li Z; Liu Y; Wang Y; Wang Y; Teng L
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35296556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase II study of perioperative pembrolizumab plus mFOLFOX in patients with potentially resectable esophagus, gastroesophageal junction (GEJ), and stomach adenocarcinoma.
    Sun W; Veeramachaneni N; Al-Rajabi R; Madan R; Kasi A; Al-Kasspooles M; Baranda J; Saeed A; Phadnis MA; Godwin AK; Olyaee M; Streeter N; Nagji A; Dai J; Williamson S
    Cancer Med; 2023 Aug; 12(15):16098-16107. PubMed ID: 37326317
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune checkpoint inhibitors in resectable gastroesophageal cancers - a review.
    Mukherjee S; Parmar K; Smyth E
    Ther Adv Med Oncol; 2022; 14():17588359221139625. PubMed ID: 36479471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of immune-checkpoint inhibitors in metastatic gastric or gastroesophageal junction adenocarcinoma by patient subgroups: A systematic review and meta-analysis.
    Kundel Y; Sternschuss M; Moore A; Perl G; Brenner B; Goldvaser H
    Cancer Med; 2020 Oct; 9(20):7613-7625. PubMed ID: 32869544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of neoadjuvant immunotherapy in resectable esophageal or gastroesophageal junction carcinoma: A pooled analysis of prospective clinical trials.
    Zhu J; Leng X; Gao B; Wang B; Zhang H; Wu L; Ma J; Tan Y; Peng L; Han Y; Wang Q
    Front Immunol; 2022; 13():1041233. PubMed ID: 36591306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MATTERHORN: phase III study of durvalumab plus FLOT chemotherapy in resectable gastric/gastroesophageal junction cancer.
    Janjigian YY; Van Cutsem E; Muro K; Wainberg Z; Al-Batran SE; Hyung WJ; Molena D; Marcovitz M; Ruscica D; Robbins SH; Negro A; Tabernero J
    Future Oncol; 2022 Jun; 18(20):2465-2473. PubMed ID: 35535555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oxaliplatin in perioperative chemotherapy for gastric and gastroesophageal junction (GEJ) adenocarcinoma.
    Fritsch R; Hoeppner J
    Expert Rev Gastroenterol Hepatol; 2019 Apr; 13(4):285-291. PubMed ID: 30791774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemotherapy and Immune Checkpoint Blockade for Gastric and Gastroesophageal Junction Adenocarcinoma.
    Manji GA; Lee S; Del Portillo A; May M; Ana SS; Alouani E; Sender N; Negri T; Gautier K; Ge L; Fan W; Xie M; Sethi A; Schrope B; Tan AC; Park H; Oberstein PE; Shah MA; Raufi AG
    JAMA Oncol; 2023 Dec; 9(12):1702-1707. PubMed ID: 37856106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of immune checkpoint inhibitors in the treatment sequence of advanced gastric or gastro-esophageal junction cancer: A systematic review and meta-analysis of randomized trials.
    Dubois M; Liscia N; Brunetti O; Ziranu P; Lai E; Argentiero A; Mazza E; Cascinu S; Silvestris N; Casadei-Gardini A; Scartozzi M
    Crit Rev Oncol Hematol; 2022 May; 173():103674. PubMed ID: 35364261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Perioperative immune checkpoint inhibitor therapy for gastric and gastroesophageal junction cancers: a review of current approaches and future perspectives.
    Takahari D; Nakayama I
    Int J Clin Oncol; 2023 Nov; 28(11):1431-1441. PubMed ID: 37500970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of neoadjuvant regimens for resectable gastroesophageal junction cancer: a systematic review of randomized clinical trials across three decades.
    Nishikawa G; Banik P; Thawani R; Kardosh A; Wood SG; Nabavizadeh N; Chen EY
    J Gastrointest Oncol; 2022 Jun; 13(3):1454-1466. PubMed ID: 35837173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant Treatment Strategies for Resectable Proximal Gastric, Gastroesophageal Junction and Distal Esophageal Cancer.
    Ahmad MU; Javadi C; Poultsides GA
    Cancers (Basel); 2022 Mar; 14(7):. PubMed ID: 35406527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Perioperative treatment and biomarker analysis of LP002, an anti-PD-L1 antibody, plus chemotherapy in resectable gastric and gastroesophageal junction cancer.
    Tang JL; Zhang B; Xu JP; Qi L; Xin D; Wang L; Wang BZ; Tian YT; Li Y; Huang J
    Cancer Med; 2023 Mar; 12(5):5639-5648. PubMed ID: 36341590
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances in clinical trials on perioperative immune checkpoint inhibitors for resectable non-small cell lung cancer: A comprehensive review.
    Cui S; Wang N; Liang Y; Meng Y; Shu X; Kong F
    Int Immunopharmacol; 2024 Nov; 141():112903. PubMed ID: 39146783
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FLOT or CROSS for gastroesophageal junction cancers-is the debate over yet?
    Shariff B; Mehta R
    Chin Clin Oncol; 2023 Jun; 12(3):24. PubMed ID: 37303220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Esophageal Cancer: New Insights into a Heterogenous Disease.
    Krug S; Michl P
    Digestion; 2017; 95(4):253-261. PubMed ID: 28384630
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.